Implementation of breast cancer continuum of care in low- and middle-income countries during the COVID-19 pandemic

Hagar Elghazawy, Joaira Bakkach, Mohamed S Zaghloul, Atlal Abusanad, Mariam Mohamed Hussein, Mohamed Alorabi, Nermean Bahie Eldin, Thanaa Helal, Tarek M Zaghloul, Bhanu Prasad Venkatesulu, Hesham Elghazaly, Sana Al-Sukhun, Hagar Elghazawy, Joaira Bakkach, Mohamed S Zaghloul, Atlal Abusanad, Mariam Mohamed Hussein, Mohamed Alorabi, Nermean Bahie Eldin, Thanaa Helal, Tarek M Zaghloul, Bhanu Prasad Venkatesulu, Hesham Elghazaly, Sana Al-Sukhun

Abstract

Breast cancer is the most common malignancy among women worldwide. The current COVID-19 pandemic represents an unprecedented challenge leading to care disruption, which is more severe in low- and middle-income countries (LMIC) due to existing economic obstacles. This review presents the global perspective and preparedness plans for breast cancer continuum of care amid the COVID-19 outbreak and discusses challenges faced by LMIC in implementing these strategies. Prioritization and triage of breast cancer patients in a multidisciplinary team setting are of paramount importance. Deescalation of systemic and radiation therapy can be utilized safely in selected clinical scenarios. The presence of a framework and resource-adapted recommendations exploiting available evidence-based data with judicious personalized use of current resources is essential for breast cancer care in LMIC during the COVID-19 pandemic.

Keywords: COVID-19; SARS-CoV-2; breast cancer; coronavirus; low- and middle-income countries; pandemic.

References

    1. World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19, 11 March 2020. . Accessed April 23 2020.
    1. World Health Organization. Coronavirus disease (COVID-19) situation reports. . Accessed April 23 2020.
    1. Liang W, Guan W, Chen R. et al. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 21(3), 335–337 (2020).
    1. Onder G, Rezza G, Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA 323(18), 1775–1776 (2020).
    1. Rothan HA, Byrareddy SN. The epidemiology and pathogenesis of coronavirus disease (COVID-19) outbreak. J Autoimmun. 109, 102433 (2020).
    1. World Bank. New country classifications by income level: 2019–2020. . Accessed April 23 2020.
    1. Al- Sukhun S, de Lima Lopes G, Jr, Gospodarowicz M. et al. Global Health Initiatives of the International Oncology Community. American Society of Clinical Oncology Educational Book. 37, 395–402 (2017).
    1. Bishr MK, Zaghloul MS. Radiation therapy availability in Africa and Latin America: two models of low and middle income countries. Int. J. Radiat. Oncol. Biol. Phys. 102(3), 490–498 (2018).
    1. Kugbey N, Ohene-Oti N, Vanderpuye V. COVID-19 and its ramifications for cancer patients in low-resource settings: Ghana as a case study. EcancermedicalsciencH 14, ed99 (2020).
    1. Bray F, Ferlay J, Soerjomataram I. et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 68(6), 394–424 (2018).
    1. Anderson BO. Breast cancer—thinking globally. Science 343(6178), 1403 (2014).
    1. McKenzie F, Zietsman A, Galukande M. et al. Drivers of advanced stage at breast cancer diagnosis in the multicountry African breast cancer - disparities in outcomes (ABCDO) study. Int. J. Cancer 142(8), 1568–1579 (2018).
    1. Al-Sukhun S, Temin S, Chavez-MacGregor M. et al. ASCO resource-stratified guidelines: methods and opportunities. J GlobOncol. 4, 1–8 (2018).
    1. Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19). . Accessed April 23 2020.
    1. Zhang L, Zhu F, Xie L. et al. Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan, China. Ann. Oncol. (2020) (Epub ahead of print) .
    1. Desai A, Sachdeva S, Parekh T. et al. COVID-19 and cancer: lessons from a pooled meta-analysis. JCO Glob Oncol. 6, 557–559 (2020).
    1. Ferlay J, Ervik M, Lam F. et al. Global Cancer Observatory: Cancer Today. Lyon, France: International Agency for Research on Cancer, 2018. . Accessed April 23 2020.
    1. COVID-19 Surveillance Group. Characteristics of COVID-19 patients dying in Italy: report based on available data on March 20th, 2020. Rome, Italy: Instituto Superiore Di Sanita. (2020).
    1. Chen N, Zhou M, Dong X. et al. Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study. Lancet Oncol. 395(10223), 507–513 (2020).
    1. Tagliamento M, Lambertini M, Genova C. et al. Call for ensuring cancer care continuity during COVID-19 pandemic. ESMO Open 5, e000783 (2020).
    1. Kuderer NM, Choueiri TK, Shah DP. et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study. Lancet 395(10241), 1907–1918 (2020).
    1. Mehta V, Goel S, Kabarriti R . et al. Case fatality rate of cancer patients with COVID-19 in a New York hospital system. Cancer Discov., (2020) (Epub ahead of print).
    1. COVID-19 rapid guideline: delivery of systemic anticancer treatments guidance. NICE guideline [NG161] Published date: 20 March 2020. . Accessed April 23 2020.
    1. Dietz JR, Moran MS, Isakoff SJ. et al. Recommendations for prioritization, treatment, and triage of breast cancer patients during the COVID-19 pandemic. The COVID-19 Pandemic Breast Cancer Consortium. Breast Cancer Res. Treat. 181, 487–497 (2020).
    1. ESMO management and treatment adapted recommendations in the COVID-19 era: breast cancer. . Accessed April 23 2020.
    1. American College of Surgeons. COVID-19 Guidelines for Triage of Breast Cancer Patients. . Accessed April 23 2020.
    1. Bartlett DL, Howe JR, Chang G. et al. Management of cancer surgery cases during the COVID-19 pandemic: considerations. Ann. Surg. Oncol. 27, 1717–1720 (2020).
    1. Curigliano G, Cardoso MJ, Poortmans P. et al. Recommendations for triage, prioritization and treatment of breast cancer patients during the COVID-19 pandemic. The Breast 52, 8–16 (2020).
    1. Al-Rashdan A, Roumeliotis M, Quirk S. et al. Adapting radiotherapy treatments for breast cancer patients during the COVID-19 pandemic: hypo-fractionation and accelerated partial breast irradiation to address World Health Organization recommendations. Adv. Radiat. Oncol. (2020) (Epub ahead of print).
    1. Combs SE, Belka C, Niyazi M. et al. First statement on preparation for the COVID-19 pandemic in large German speaking university-based radiation oncology departments. Radiat. Oncol. 15(1), 74 (2020).
    1. Filippi AR, Russi E, Magrini SM. et al. Letter from Italy: first practical indications for radiation therapy departments during COVID-19 outbreak. Int. J. Radiat. Oncol. Biol. Phys. (2020) (Epub ahead of print).
    1. Jazieh A-R, Al Hadab A, Al Olayan A. et al. Managing oncology services during a major coronavirus outbreak: lessons from the Saudi Arabia experience. JCO Glob. Oncol. 6, 18–524 (2020).
    1. Ngoi N, Lim J, Ow S. et al. A segregated-team model to maintain cancer care during the COVID-19 outbreak at an academic center in Singapore. Ann. Oncol. (2020) (Epub ahead of print).
    1. World Health Organization. Water, sanitation, hygiene, and waste management for the COVID-19 virus: interim guidance. Available at: . Accessed April 23 2020.
    1. Centers for Disease Control and Prevention (CDC). Coronavirus Disease 2019 (COVID-19). Prevent getting sick. Available at: . Accessed April 23 2020.
    1. Wang Z, Wang J, He J. Active and effective measures for the care of patients with cancer during the COVID-19 spread in China. JAMA Oncol. (2020) (Epub ahead of print).
    1. Motlagh A, Yamrali M, Azghandi S. et al. COVID19 prevention & care: a cancer specific guideline. Arch. Iran. Med. 23(4), 255–264 (2020).
    1. Al-Shamsi HO, Alhazzani W, Alhuraiji A. et al. A practical approach to the management of cancer patients during the novel Coronavirus Disease 2019 (COVID-19) pandemic: an international collaborative group. The Oncologist 25, 1–10 (2020).
    1. American Society for Clinical Oncology special report: a guide to cancer care delivery during the COVID-19 pandemic. . Accessed June 25 2020.
    1. Uzzo RG, Kutikov A, Geynisman DM. Coronavirus disease 2019 (COVID-19): cancer care during the pandemic (2020).
    1. American Society for Clinical Oncology. COVID-19 Patient Care Information. . Accessed April 23 2020.
    1. Hanna TP, Evans GA, Booth CM. Cancer, COVID-19 and the precautionary principle: prioritizing treatment during a global pandemic. Nat. Rev. Clin. Oncol. 17(5), 268–270 (2020).
    1. Neto MLR, Almeida HG, Esmeraldo JD. et al. When health professionals look death in the eye: the mental health of professionals who deal daily with the 2019 coronavirus outbreak. Psychiatry Res. 288, 112972 (2020).
    1. Nacoti M, Ciocca A, Giupponi A. et al. At the epicenter of the Covid-19 pandemic and humanitarian crises in Italy: changing perspectives on preparation and mitigation. N. Engl.J. Med. Catal. (2020) (Epub ahead of print).
    1. Li R, Pei S, Chen B. et al. Substantial undocumented infection facilitates the rapid dissemination of novel coronavirus (SARS-CoV2). Science 368(6490), 489–493 (2020).
    1. Chen CC, Chi CY. Biosafety in the preparation and processing of cytology specimens with potential coronavirus (COVID-19) infection: perspectives from Taiwan: cytopathological biosafety of COVID-19. Cancer Cytopathol. (2020) (Epub ahead of print).
    1. Porzio G, Cortellini A, Bruera E. et al. Home care for cancer patients during COVID-19 pandemic: the double triage protocol. J. Pain Symptom Manage. (2020) (Epub ahead of print).
    1. Simcock R, Thomas TV, Estes C. et al. COVID-19: global radiation oncology's targeted response for pandemic preparedness. Clin. Transl. Radiat. Oncol. 22, 55–68 (2020).
    1. NHS . Clinical guide for the management of non coronavirus patients requiring acute treatment: Cancer .
    1. American College of Surgeons. Recommendations for Prioritization, Treatment and Triage of Breast Cancer Patients During the COVID-19 Pandemic: Executive Summary. Accessed April 23 2020.
    1. ASBrS and ACR Joint Statement on Breast Screening Exams During the COVID-19 Pandemic. . Accessed April 23 2020.
    1. American College of Surgeons. COVID-19: Elective Case Triage Guidelines for Surgical Care. . Accessed April 23 2020.
    1. van Doremalen N, Bushmaker T, Morris DH. et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N. Eng. J. Med. 382(16), 1564–1567 (2020).
    1. World Health Organization (WHO), Technical guidance on COVID-19.. Accessed April 23 2020.
    1. Livi L, Meattini I, Marrazzo L. et al. Accelerated partial breast irradiation using intensity-modulated radiotherapy versus whole breast irradiation: 5-year survival analysis of a phase 3 randomised controlled trial. Eur. J. Cancer 51(4), 451–463 (2015).
    1. Vaidya JS, Bulsara M, Wenz F. et al. Reduced mortality with partial-breast irradiation for early breast cancer: a meta-analysis of randomized trials. Int. J. Radiat. Oncol. Biol. Phys. 96(2), 259–265 (2016).
    1. Brunt AM, Wheatley D, Yarnold J. et al. Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial. Radiother. Oncol. 120(1), 114–118 (2016).
    1. Agrawal RK, Alhasso A, Barrett-Lee PJ. et al. First results of the randomised UK FAST Trial of radiotherapy hypofractionation for treatment of early breast cancer (CRUKE/04/015). Radiother. Oncol. 100(1), 93–100 (2011).
    1. Brunt AM, Haviland J, Sydenham M. et al. FAST Phase III RCT of Radiotherapy Hypofractionation for Treatment of Early Breast Cancer: 10-Year Results (CRUKE/04/015). Int. J. Radiat. Oncol. Biol. Phys. 102(5), 1603–1604 (2018).
    1. Vicini FA, Cecchini RS, White JR. et al. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet Oncol. 394(10215), 2155–2464 (2019).
    1. Vaidya JS, Wenz F, Bulsara M. et al. Risk-adapted targeted intraoperative radiotherapy versus whole-breast radiotherapy for breast cancer: 5-year results for local control and overall survival from the TARGIT-A randomised trial. Lancet 383(9917), 603–613 (2014).
    1. Coles CE, Aristei C, Bliss J. et al. International guidelines on radiation therapy for breast cancer during the COVID-19 pandemic. Clin. Oncol. 32(5), 279–281 (2020).
    1. Haviland JS, Owen JR, Dewar JA. et al. The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials. Lancet Oncol. 14(11), 1086–1094 (2013).
    1. Whelan TJ, Julian JA, Shelley W. et al. Long-term results of hypofractionated radiation therapy for breast cancer. N. Engl. J. Med. 362(6), 513–520 (2010).
    1. Brunt AM, Haviland J, Sydenham M . et al. OC-0595: FAST-Forward phase 3 RCT of 1-week hypofractionated breast radiotherapy:3-year normal tissue effects. Radiother. Oncol. 127, S311–S312 (2018).
    1. Bloomfield DJ. Development of postoperative radiotherapy for breast cancer: UK consensus statements — a model of patient, clinical and commissioner engagement? Clin. Oncol. 29(10), 639–641 (2017).
    1. Wang S-L, Fang H, Song Y-W. et al. Hypofractionated versus conventional fractionated postmastectomy radiotherapy for patients with high-risk breast cancer: a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol. 20(3), 352–360 (2019).
    1. Ragaz J, Jackson SM, Le N. et al. Adjuvant radiotherapy and chemotherapy in node-positive premenopausal women with breast cancer. N. Engl. J. Med. 337(14), 956–962 (1997).
    1. Bartlett FR, Donovan EM, McNair HA. et al. The UK HeartSpare Study (Stage II): multicentre evaluation of a voluntary breath-hold technique in patients receiving breast radiotherapy. Clin. Oncol. 29(3), e51–56 (2017).
    1. Mulvenna P, Nankivell M, Barton R. et al. Dexamethasone and supportive care with or without whole brain radiotherapy in treating patients with non-small cell lung cancer with brain metastases unsuitable for resection or stereotactic radiotherapy (QUARTZ): results from a phase 3, non-inferiority, randomised trial. Lancet. 388(10055), 2004–2014 (2016).
    1. Borgelt B, Gelber R, Kramer S. et al. The palliation of brain metastases: final results of the first two studies by the radiation therapy oncology group. Int. J. Radiat. Oncol. Biol. Phys. 6(1), 1–9 (1980).
    1. Chow R, Hoskin P, Schild SE. et al. Single vs multiple fraction palliative radiation therapy for bone metastases: cumulative meta-analysis. Radiother. Oncol. 141, 56–61 (2019).
    1. Hoskin PJ, Hopkins K, Misra V. et al. Effect of single-fraction vs multifraction radiotherapy on ambulatory status among patients with spinal canal compression from metastatic cancer: The SCORAD randomized clinical trial. JAMA 322(21), 2084 (2019).
    1. Thirion PG, Dunne MT, Kelly PJ. et al. Non-inferiority randomised phase 3 trial comparing two radiation schedules (single vs. five fractions) in malignant spinal cord compression. Br. J. Cancer 122(9), 1315–1323 (2020).
    1. Chow E, Harris K, Fan G. et al. Palliative radiotherapy trials for bone metastases: a systematic review. JCO 25(11), 1423–1436 (2007).
    1. Choi HS, Jang HS, Kang KM. et al. Symptom palliation of hypofractionated radiotherapy for patients with incurable inflammatory breast cancer. Radiat. Oncol. 14(1), 110 (2019).
    1. Silva SB, Pereira AAL, Marta GN. et al. Clinical impact of adjuvant radiation therapy delay after neoadjuvant chemotherapy in locally advanced breast cancer. Breast 38, 39–44 (2018).
    1. Olivotto IA, Lesperance ML, Truong PT. et al. Intervals longer than 20 weeks from breast-conserving surgery to radiation therapy are associated with inferior outcome for women with early-stage breast cancer who are not receiving chemotherapy. J. Clin. Oncol. 27(1), 16–23 (2009).
    1. Matuschek C, Bölke E, Haussmann J. et al. The benefit of adjuvant radiotherapy after breast conserving surgery in older patients with low risk breast cancer- a meta-analysis of randomized trials. Radiat. Oncol. 12(1), 60 (2017).
    1. Kunkler IH, Williams LJ, Jack WJL. et al. Breast-conserving surgery with or without irradiation in women aged 65 years or older with early breast cancer (PRIME II): a randomised controlled trial. Lancet Oncol. 16(3), 266–273 (2015).
    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J. Natl Cancer Inst. Monogr. 2010(41), 162–177 (2010).
    1. Jones HA, Antonini N, Hart AAM. et al. Impact of pathological characteristics on local relapse after breast-conserving therapy: a subgroup analysis of the EORTC Boost Versus No Boost Trial. J. Clin. Oncol. 27(30), 4939–4947 (2009).
    1. Naoum GE, Salama L, Ho A. et al. The impact of chest wall boost on reconstruction complications and local control in patients treated for breast cancer. Int. J. Radiat. Oncol. Biol. Phys. 105(1), 155–164 (2019).
    1. Bartelink H, Maingon P, Poortmans P. et al. Whole-breast irradiation with or without a boost for patients treated with breast-conserving surgery for early breast cancer: 20-year follow-up of a randomised phase 3 trial. Lancet Oncol. 16(1), 47–56 (2015).
    1. Willeumier JJ, van der Linden YM, Dijkstra PDS. Lack of clinical evidence for postoperative radiotherapy after surgical fixation of impending or actual pathologic fractures in the long bones in patients with cancer; a systematic review. Radiother. Oncol. 121(1), 138–142 (2016).
    1. Shankar A, Saini D, Roy S. et al. Cancer care delivery challenges amidst Coronavirus Disease – 19 (COVID-19) outbreak: specific precautions for cancer patients and cancer care providers to prevent spread. Asian Pac. J. Cancer Prev. 21(3), 569–573 (2020).
    1. Russell B, Moss C, Rigg A. et al. COVID-19 and treatment with NSAIDs and corticosteroids: should we be limiting their use in the clinical setting? Ecancermedicalscience 14, 1023 (2020).
    1. Federal Agency for Medicines and Health Products (FAMHP). Coronavirus (COVID-19). . Accessed April 23 2020.
    1. Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir. Med. 8(4), e21 (2020).
    1. Amici C, Caro AD, Ciucci A. et al. Indomethacin has a potent antiviral activity against SARS coronavirus. Antivir. Ther. 11(8), 1021–1030 (2006).
    1. The Renal Association. UK position statement on COVID-19 and ACE Inhibitor/Angiotensin Receptor Blocker use. . Accessed April 23 2020.
    1. The European Society of Cardiology (ESC). Position Statement of the ESC Council on Hypertension on ACE-Inhibitors and Angiotensin Receptor Blockers. . Accessed April 23 2020
    1. American Heart Association. HFSA/ACC/AHAstatement addresses concerns re: using RAAS antagonists in COVID-19. . Accessed April 23 2020.
    1. Nawar T, Morjaria S, Kaltsas A, Patel et al. Granulocyte-colony stimulating factor in COVID-19: is it stimulating more than just the bone marrow? .Am. J. Hematol. (2020) (Epub ahead of print).
    1. The Lancet Oncology. COVID-19: global consequences for oncology. Lancet Oncol. 21(4), 467 (2020).
    1. BBC News. Coronavirus: GP surgery apology over ‘do not resuscitate’ form. . Accessed April 23 2020.
    1. Curtis JR, Kross EK, Stapleton RD. The importance of addressing advance care planning and decisions about do-not-resuscitate orders during novel Coronavirus 2019 (COVID-19). JAMA 323(18), 1771–1772 (2020).
    1. Pratt B, Van C, Cong Y. et al. Perspectives from South and east Asia on clinical and research ethics: a literature review. J. Emp. Res. Hum. Res. Eth. 9, 52–67 (2014).
    1. Leung K, Wu JT, Liu D. et al. First-wave COVID-19 transmissibility and severity in China outside Hubei after control measures, and second-wave scenario planning: a modelling impact assessment. Lancet. 395(10233), 1382–1393 (2020).
    1. Chen W-H, Strych U, Hotez PJ. et al. The SARS-CoV-2 vaccine pipeline: an overview. Curr. Trop. Med. Rep. 3, 1–4 (2020).
    1. Ferguson N, Laydon D, NedjatiGilani G. et al. Report 9: impact of non-pharmaceutical interventions (NPIs) to reduce COVID19 mortality and healthcare demand. London: Imperial College London, March 16, 2020.
    1. Vanderpuye V, Elhassan MMA, Simonds H. Preparedness for COVID-19 in the oncology community in Africa. Lancet Oncol. 21(5), 621–622 (2020).
    1. Ginsburg O, Rositch A, Conteh L. et al. Breast cancer disparities among women in low- and middle-income countries. Curr. Breast Cancer Rep. 10(3), 179–186 (2018).
    1. Zhan QH, Fu JQ, Fu FM, Zhang J, Wang C. Survival and time to initiation of adjuvant chemotherapy among breast cancer patients: a systematic review and meta-analysis. Oncotarget 9(2), 2739–2751 (2017).
    1. Ho PJ, Cook AR, Binte Mohamed Ri NK. et al. Impact of delayed treatment in women diagnosed with breast cancer: a population-based study. Cancer Med. 9(7), 2435–2444 (2020).
    1. Tfayli A, Temraz S, Abou Mrad R. et al. Breast cancer in low- and middle-income countries: an emerging and challenging epidemic. J. Oncol. 2010, (2010).
    1. Anderson BO, Yip C-H, Smith RA. et al. Guideline implementation for breast healthcare in low-income and middle-income countries: overview of the Breast Health Global Initiative Global Summit 2007. Cancer 13(Suppl. 8), 2221–2243 (2008).
    1. Dizon JM, Machingaidze S, Grimmer K. To adopt, to adapt, or to contextualise? The big question in clinical practice guideline development. BMC Res. Notes 9(1), 442 (2016).
    1. Emanuel EJ, Persad G, Upshur R. et al. Fair allocation of scarce medical resources in the time of COVID-19. N. Engl. J. Med. 382(21), 2049–2055 (2020).
    1. Farrell TW, Ferrante LE, Brown T. et al. AGS Position Statement: Resource Allocation Strategies and Age-Related Considerations in the COVID-19 Era and Beyond. J. Am. Geriatr. Soc. 68(6), 1136–1142 (2020).
    1. Trapani D, Curigliano G. How can biosimilars change the trajectory of breast cancer therapy? Expert Rev. Anticancer Ther. 20(5), 325–328 (2020).
    1. WHO Technical Report Series The Selection and Use of Essential Medicines. Report of the WHO Expert Committee on Selection and Use of Essential Medicines, 2019 (including the 21st WHO Model List of Essential Medicines and the 7th WHO Model List of Essential Medicines for Children). . Accessed June 25 2020.
    1. Miller EM, Schwartzberg LS. Biosimilars for breast cancer: a review of HER2-targeted antibodies in the United States. Ther. Adv. Med. Oncol. 11, 1758835919887044 (2019).
    1. International Atomic Energy Agency. Radiotherapy in Cancer Care: Facing the Global Challenge, IAEA, Vienna (2017). . Accessed June 25 2020.
    1. Randolph HE, Barreiro LB. Herd immunity: understanding COVID-19. Immunity 52(5), 737–741 (2020).
    1. Blumenthal SJ, Kagen J. The effects of socioeconomic status on health in rural and urban America. JAMA 287(1), 109–109 (2002).
    1. Hazin R, Qaddoumi I. Teleoncology: current and future applications for improving cancer care globally. Lancet Oncol. 11(2), 204–210 (2010).
    1. Martei YM, Pace LE, Brock JE. et al. Breast cancer in low- and middle-income countries: why we need pathology capability to solve this challenge. Clin. Lab. Med. 38(1), 161–173 (2018).
    1. Centers for Disease Control and Prevention (CDC) Coronavirus Disease 2019 (COVID-19). Prevent getting sick. Accessed April 23, 2020.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe